News for TG Therapeutics, Inc. (0VGI.L)

Summary TG Therapeutics Inc (TGTX), a biopharmaceutical company specializing in treatments for B-cell diseases, announced that its Chairman and CEO, Michael S.

TG Therapeutics (TGTX) to participate in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Michael S. Weiss to join a fire

**media[647619]**

Summary TG Therapeutics Inc (TGTX), a biopharmaceutical company specializing in treatments for B-cell diseases, announced that its Chairman and CEO, Michael S.

Fireside chat scheduled for Wednesday, June 4, 2025, at 12:50pm ET NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX) today announced

Summary TG Therapeutics Inc (TGTX) announced the presentation of data on BRIUMVI® (ublituximab-xiiy) for patients with relapsing forms of multiple sclerosis (R

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy)

Summary TG Therapeutics Inc (TGTX) has announced its presentation schedule for the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, taking p

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublit

TG Therapeutics (TGTX) will present new BRIUMVI® data at the 2025 CMSC Annual Meeting. The key presentations will focus on long-term ublituximab treatm

**media[637912]**

Strengths: FDA approval of BRIUMVI and a robust pipeline of B-cell disease treatments.Weaknesses: Dependence on BRIUMVI sales and the need for additional capit

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology […]

Operator: Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast. At this time, all participants are in a listen-only mode.

US Net Sales for BRIUMVI: Approximately $119.7 million in Q1 2025, reflecting 137% year-over-year growth and 16% sequential quarter-over-quarter growth.Full Ye

May 05, 2025 / 12:30PM GMTOperator Greetings and welcome to TG Therapeutics first quarter conference call and webcast. (Operator Instructions) As a reminder, th

TG Therapeutics' earnings miss forecast, but revenue exceeds expectations. Revised revenue projections showcase strong business momentum. Analysts in

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.2% on Monday. The Dow traded up 0.21% to 41,406.25 while the NASDAQ ...

Looking into the current session, TG Therapeutics Inc. TGTX shares are trading at $36.50, after a 0.57% decrease. Over the past month, the stock decreased by 3....